放疗后血清Hsp70升高与NK细胞降低或可预测乳腺癌复发
该研究纳入40例接受保乳手术及辅助放疗的乳腺癌患者,纵向检测血清游离Hsp70及淋巴细胞亚群。放疗结束至结束后6周血清Hsp70较高者,2年内出现对侧复发或转移的风险显著更高,且复发/转移患者放疗后NK细胞计数更低。提示放疗后Hsp70持续升高和NK细胞下降可能预测不良预后。
要点
- 放疗结束至结束后6周血清Hsp70较高与2年内对侧复发或转移显著相关。
- 复发/转移患者放疗后NK细胞计数低于无病患者,T、B细胞比例无显著变化。
- 年龄、肿瘤大小、分级、TNM分期、辅助化疗及照射剂量未影响血清Hsp70水平。
核心结论
- 放疗后6周内血清游离Hsp70持续升高及NK细胞计数下降可能预测乳腺癌患者预后不良。
研究设计与样本
- 研究纳入40例接受保乳手术和辅助放疗的乳腺癌患者,纵向采集放疗前、30 Gy、60 Gy、放疗后6周、6个月和1年的血清。
- 采用R&D Human HSP70 DuoSet和lipHsp70 ELISA检测可溶性游离Hsp70,多参数流式细胞术分析外周血淋巴细胞亚群。
- 临床反应随访至放疗后5年。
主要发现
- 放疗结束(t3)时血清Hsp70较高者2年内发生对侧复发或转移的风险显著更高(p=0.03)。
- 放疗后6周(t4)血清Hsp70较高者2年内发生对侧复发或转移的风险显著更高(p=0.007)。
- 复发/转移患者放疗后NK细胞计数低于无病患者,T细胞和B细胞比例无显著变化。
- 年龄、肿瘤大小、分级、TNM分期、辅助化疗及照射剂量未显著影响血清Hsp70水平。
临床怎么用
- 对于保乳术后辅助放疗的乳腺癌患者,可考虑在放疗结束至结束后6周监测血清游离Hsp70和NK细胞计数。
- Hsp70持续升高且NK细胞计数下降的患者可能需加强随访或进一步评估复发风险。
局限性
- 样本量较小(40例),结论需更大规模研究验证。
- Hsp70和NK细胞作为预测标志物的临界值未在本文中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is the most common invasive tumor in women worldwide and the second cause of cancer-related deaths. After breast conserving surgery the tumor bed gets irradiated. Radiation-induced tumor cell death has been found to be associated with the release of damage-associated molecular patterns (DAMPs) including free Hsp70 that can stimulate inflammatory immune responses. Therefore, Hsp70 serum levels as well as the composition of lymphocyte subpopulations have been measured in breast cancer patients during therapy and in the follow-up period as potential predictors for clinical outcome. METHODS: The serum of 40 breast cancer patients, who received a breast-conserving surgery and adjuvant radiotherapy (RT) was examined for soluble, free Hsp70 using the R&D Human HSP70 DuoSet and lipHsp70 ELISA. Lymphocyte subpopulations and total lymphocyte counts were analysed by multiparameter flow cytometry in the peripheral blood. Blood samples were collected before (t1), after 30 Gy (t2) and 60 Gy (t3), 6 weeks (t4), 6 months (t5) and 1 year (t6) after RT. Clinical responses were assessed regularly up to 5 years after RT. RESULTS: Patients who developed a contralateral recurrence or metastases within the first 2 years after RT had significantly higher serum Hsp70 values at the end of RT (t3; p = 0.03) up to 6 weeks after RT (t4; p = 0.007) compared to patients who either remained disease-free or developed a secondary endometrial carcinoma. Clinicopathological parameters such as age, tumor size, grading and TNM-stage of the resected tumors, adjuvant chemotherapy and irradiation dose did not affect serum Hsp70 levels. Elevated free Hsp70 levels might be indicative for a chronic inflammatory response which could support tumor recurrence. Lymphocyte subpopulation analysis revealed lower NK cell counts after RT in recurrence/metastases patients as compared to disease-free patients. In contrast, no significant changes were observed in the proportion of T and B cells. CONCLUSION: Longitudinal elevated serum levels of free Hsp70 up to 6 weeks after RT and dropping NK cell counts might be predictive for an unfavourable prognosis in patients with breast cancer.
引用
- Rothammer A, Sage EK, Werner C, et al. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence? Radiat Oncol. 2019. PMID: 31077235. doi:10.1186/s13014-019-1286-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。